PDCD1 and melanoma: Yan et al.33 has shown that CX3CR1+ CD8+ T cells withstand chemotherapy during anti-PD-1 therapy in a few melanoma patients, suggesting the potential utility of CX3CR1 expression on circulating CD8+ T cells.